Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: A life or death issue

Critical Reviews in Immunology

Volumn 21, Issue 5, 2001, Pages 399-425

  Mills, Charles D ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

Arginase; Dendritic cells; Macrophages; Nitric oxide; Ornithine

Indexed keywords

ARGININE; CITRULLINE; COLLAGEN; NITRIC OXIDE; ORNITHINE; POLYAMINE; UREA;

AMINO ACID METABOLISM; DEATH; DENDRITIC CELL; HOST CELL; IMMUNE RESPONSE; LIFE; MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL;

ANIMALS; ARGINASE; ARGININE; CELL DEATH; CELL SURVIVAL; CITRULLINE; HUMANS; LYMPHOCYTES; MACROPHAGES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; ORNITHINE; UREA;

EID: 0035727293     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (231)

1. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells
2. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite
3. Nitric oxide, a cytotoxic activated macrophage effector molecule
4. Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages
5. Suppression of in vitro cytotoxic response by macrophages due to induced arginase
6. Activated macrophages kill tumour cells by releasing arginase
7. M-1/M-2 macrophages the Th1/Th2 paradigm
8. Macrophages and the immune response
9. Arginine metabolism, nitric oxide and beyond
10. Nitric oxide and macrophage function
11. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity
12. Nitric oxide-releasing polymers containing the [N(O)NO]-group
13. Autocrine/paracrine IFN-alpha/beta mediates the lipopolysaccharide-induced activation of transcription factor Statlalpha in mouse macrophages: Pivotal role of Statlalpha in induction of the inducible nitric oxide synthase gene
14. Triggering of peritoneal macrophages with IFN-alpha/beta attenuates the expression of inducible nitric oxide synthase through a decrease in NF-kappaB activation
15. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: Phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression
16. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: Its implications in IL-13-inhibited nitric oxide production
17. Cutting edge, Stat6-dependent substrate depletion regulates nitric oxide production
18. Microenvironmental arginine depletion by macrophages in vivo
19. Arginine metabolism in wounds
20. Arginase, an antimitotic agent in tissue culture
21. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells
22. Mammalian nitrate biosynthesis, mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide
23. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma
24. Regulation of macrophage functions by L-arginine
25. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells
26. Regulation of macrophage physiology by L-arginine: Role of the oxidative L-arginine deiminase pathway
27. Role of nitric oxide synthesis in macrophage antimicrobial activity
28. Signal transduction mechanisms involving nitric oxide
29. Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion
30. Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria
31. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine
32. Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase pathway
33. Suppressor macrophages
34. Nitric oxide-mediated apoptosis in murine peritoneal macrophages
35. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
36. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide
37. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
38. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
39. Novel effects of nitric oxide
40. Inhibition of nitric oxide synthase in experimental gramnegative sepsis
41. Altered responses to bacterial infection and endotoxic shockin mice lacking inducible nitric oxide synthase
42. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity
43. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production
44. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin2 therapy
45. Polyamines in mammalian biology and medicine
46. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy
47. Increased ornithine decarboxylase activity and polyamine biosynthesis are required for optimal cytolytic T lymphocyte induction
48. Bacterial lipopolysaccharide induction of ornithine decarboxylase in the macrophage-like cell line RAW264, requirement of an inducible soluble factor
49. Glutamine metabolism in rat skeletal muscle wounded with lambda-carrageenan
50. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide
51. IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages
52. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation
53. H2 cytokines
54. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway
55. Cell fate in the immune system: Decisions, decisions, decisions
56. Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon γ
57. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide
58. Characterization of the effects of endotoxin on macrophage tumor cell killing
59. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages
60. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2
61. Microbial lipopeptides stimulate dendritic cell maturation via toll-like receptor 2
62. Endotoxintolerant mice have mutations in Toll-like receptor 4 (Tlr4)
63. Cutting edge, Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product
64. Receptor mediated subversion of macrophage cytokine production by intracellular pathogens
65. Leishmania major-parasitized macrophages augment Th2-type T cell activation
66. Induction of direct antimicrobial activity through mammalian toll-like receptors
67. Toll-like receptor-2 mediates mycobacteriainduced proinflammatory signaling in macrophages
68. Differential roles of TLR2 and TLR4 in recognition of gramnegative and gram-positive bacterial cell wall components
69. Deactivation of macrophages by transforming growth factor-beta
70. Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma
71. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta
72. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production
73. Transforming growth factor type beta, rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
74. TGF-beta in infections and infectious diseases
75. Characterization of latent TGF-β activation by murine peritoneal macrophages
76. Expression and secretion of type beta transforming growth factor by activated human macrophages
77. Infection of murine macrophages with Toxoplasma gondii is associatedwith release of transforming growth factor beta and downregulation of expression of tumor necrosis factor receptors
78. Production of transforming growth factor-beta by Mycobacterium avium-infected human macrophages is associated with unresponsiveness to IFN-gamma
79. Insulin down-regulates the inducible nitric oxide synthase pathway, nitric oxide as cause and effect of diabetes?
80. Decreased production of TGF-beta 1 by human alveolar macrophages compared with blood monocytes
81. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity
82. Differential regulation ofmacrophage arginine, metabolism, a proposed role in wound healing
83. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1
84. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring
85. Blockade of type 1 beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat
86. N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine
87. Stimulation of peritoneal cell arginase by bacterial lipopolysaccharides
88. Temporal expression of different pathways of L-arginine metabolism in healing wounds
89. Lymphocyte mediation of lipopolysaccharide-stimulated macrophage metabolism
90. The specific amino acid requirements of a mammalian cell (strain 1) in tissue culture
91. Some aspects of the role of arginine and arginase in mouse carcinoma
92. Arginine catabolism by microorganisms
93. Arginine deiminase
94. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells
95. Induction of intracellular arginase activity does not diminish the capacity of macrophages to produce nitric oxide in vitro
96. Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells
97. Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide
98. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells
99. Plasma arginine, citrulline, and ornithine kinetics in adults, with observations on nitric oxide synthesis
100. Arginine, an essential amino acid for injured rats
101. The inhibition of arginase by n(omega)-hydroxy-L-arginine controls the growth of leishmania inside macrophages
102. + T cells through IL-12 produced by Listeria-induced macrophages
103. + T cells
104. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis
105. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain
106. Effects of IL-12 on immune responses to microbial infections, a key mediator in regulating disease outcome
107. Expression of IL-18 by Mycobacterium avium-infected human monocytes; association with M. avium virulence
108. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium, killing effector mechanism depends on the generation of reactive nitrogen intermediates
109. Interleukin 10 inhibits macrophage microbicidal activity byblockingthe endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation
110. Nitric oxide and nitric oxide synthase mRNA induction in mouse islet cells by interferon-gamma plus tumor necrosis factor-alpha
111. Tumor necrosis factor enhances interferoninduced Ia antigen expression on murine islet parenchymal cells
112. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10
113. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bonemarrow-derived macrophages
114. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages
115. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans
116. Tumorinduced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2
117. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages
118. +T cells correlates with Th1/Th2 phenotype
119. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection
120. Type 1 interferon (IFN alpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite
121. Interferon beta in multiple sclerosis: Is IL-12 suppression the key?
122. The neglected role of type I interferon in the T-cell response: Implications for its clinical use
123. + lymphocytes
124. + lymphocytes by inhibiting IL-12 production
125. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids
126. Macrophage stimulating protein
127. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase
128. An alternate mechanism of glucocorticoid anti-proliferative effect: Promotion of a Th2 cytokine-secreting profile
129. Regulation of the RON receptor tyrosine kinase expression in macrophages: Blocking the RON gene transcription by endotoxin-induced nitric oxide
130. Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury
131. Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase
132. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide
133. IL-1 beta-induced inhibition of beta-cell function is mediated through nitric oxide
134. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans
135. Induction of interleukin 1 secretion and of tumoricidal activity in macrophages are not closely related phenomena
136. Simulation ofthe diffusion and reaction of endogenously produced nitric oxide
137. Counterprotective effect of erythrocytes in experimental bacterial peritonitis is due to scavenging of nitric oxide and reactive oxygen intermediates
138. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages
139. Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide
140. Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide
141. Superoxide formation and macrophage resistance to nitric oxide-mediated apoptosis
142. Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. Evidence for involvement of nuclear factor-kappa B activation
143. Tolerance, danger, and the extended family
144. An innate sense of danger
145. Single-step labeling of DNA using restriction endonucleases and T4 polynucleotide kinase
146. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
147. Nitric oxide in autoimmunity and cell transplantation
148. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta
149. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: Induction of receptor tyrosine phosphorylation and cell migration
150. Overexpression of the RON gene in human breast carcinoma
151. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum
152. The systemic administration of gamma interferon inhibits collagen synthesis and acute inflammation in a murine skin wounding model
153. The role of inflammatory cytokines in wound healing: Accelerated healing in endotoxin-resistant mice
154. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses
155. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages
156. Low response of BALB/c macrophages to priming and activating signals
157. Modulating the immune response with dendritic cells and their growth factors
158. Manipulation of costimulatory signals to enhance antitumor T-cell responses
159. Adoptive T cell therapy of tumors, mechanisms operative in the recognition and elimination of tumor cells
160. An immunostimulation theory of tumor development
161. The immune reaction as a stimulator of tumor growth
162. Macrophage requirement for growth of a murine fibrosarcoma
163. Molecular repair, wound healing, and carcinogenesis: Tumor production a possible overhealing?
164. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells
165. Macrophage arginine metabolism and the inhibition or stimulation of cancer
166. Decreased macrophage-mediated cytotoxicity in mammary-tumor-bearing mice is related to alteration of nitric-oxide production and/or release
167. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers
168. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor
169. Nitric oxide is an important mediator for tumoricidal activity in vivo
170. Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine
171. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine
172. Role of nitric oxide in tumour progression: Lessons from human tumours
173. Evidence of suppressor cell activityin spleens of mice bearing primary tumors induced by Moloney sarcoma virus
174. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice
175. Suppression of the immune response in tumor-bearing mice. II. Characterization of adherent suppressor cells
176. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses
177. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
178. Augmentation of an antitumor CTL response In vivo by inhibition of suppressor macrophage nitric oxide
179. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine
180. Macrophage microbicidal mechanisms in vivo, reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani
181. Identification of nitric oxide synthase as a protective locus against tuberculosis
182. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13
183. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene
184. Macrophage nitric oxide mediates immunosuppression in infectious inflammation
185. In vivo blockage of nitric oxide with aminoguanidine inhibits immunosuppression induced by an attenuated strain of Salmonella typhimurium, potentiates Salmonella infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen
186. T-cell hyporesponsiveness induced by activated macrophages through nitric oxide production in mice infected with Mycobacterium tuberculosis
187. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells
188. Presence of a macrophage-mediated suppressor cell mechanism during cell-mediated immune response in experimental visceral leishmaniasis
189. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins
190. A dichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice
191. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii
192. The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis
193. Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection
194. Mice lacking inducible nitric-oxide synthase are more susceptible to herpes simplex virus infection despite enhanced Th1 cell responses
195. Rapid interferon gammadependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice
196. Expression of the inducible nitric oxide synthase. Correlation with neuropathology and clinical features in mice with lymphocytic choriomeningitis
197. Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide (NO) production in astrocytes: Astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome
198. Nitric oxide synthase expression and apoptotic cell death in brains of AIDS and AIDS dementia patients
199. Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation, pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex
200. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: Suppressive effects of IL-12 boost are mediated by nitric oxide
201. Nitric oxidein autoimmune disease, cytotoxic or regulatory mediator?
202. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients
203. Suppression of arthritis by an inhibitor of nitric oxide synthase
204. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease, increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine
205. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis
206. Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors
207. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats
208. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis
209. Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene
210. Interleukin 12 protects from a T helpertype 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis
211. Arginase in glomerulonephritis
212. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat
213. Nitric oxide production by mouse sponge matrix allograft-infiltrating cells. Comparison with the rat species
214. Nitric oxide production in response to allogeneic heart transplant in mice
215. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways
216. Nitric oxide mediates early dysfunction of rat and mouse islets after transplantation
217. Nitric oxide, a pathogenetic factor in autoimmunity
218. TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype
219. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes
220. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: Activation of cyclooxygenase by nitric oxide
221. Pancreatic islet cells are highlysusceptible towards the cytotoxic effects of chemically generated nitric oxide
222. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow
223. Dendritic cells and the control of immunity
224. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo
225. CD8alpha+ and CD8alpha-subclasses of dendritic cells direct the development of distinct T helper cells in vivo
226. Reciprocal control of T helper cell and dendritic cell differentiation
227. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal
228. Nitric oxide-induced anti-mitogenic effects in high and low responder rat strains
229. Nitric oxide in Tanzanian children with malaria. Inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression
230. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients
231. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease